Stay updated on Trastuzumab Deruxtecan in HER2 Mutant NSCLC Clinical Trial

Sign up to get notified when there's something new on the Trastuzumab Deruxtecan in HER2 Mutant NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Trastuzumab Deruxtecan in HER2 Mutant NSCLC Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    A site-wide NIH notice announces updates and FAQs about federal agencies’ transition from using “Artificial Intelligence” to “Super Intelligence.”
    Difference
    0.6%
    Check dated 2026-10-26T15:57:01.000Z thumbnail image
  2. Check
    9 days ago
    Change Detected
    Summary
    The footer’s ClinicalTrials.gov revision label was updated from v3.7.1 to v3.7.2.
    Difference
    0.1%
    Check dated 2026-10-19T15:48:41.000Z thumbnail image
  3. Check
    16 days ago
    Change Detected
    Summary
    The footer revision identifier was updated from v3.7.0 to v3.7.1.
    Difference
    0.1%
    Check dated 2026-10-12T15:48:14.000Z thumbnail image
  4. Check
    37 days ago
    Change Detected
    Summary
    The study record history now shows the latest revision (v3.7.0) for the page, indicating an update to the record. The older revision (v3.6.6) has been removed from the visible history.
    Difference
    0.1%
    Check dated 2026-09-21T20:45:24.000Z thumbnail image
  5. Check
    58 days ago
    Change Detected
    Summary
    The study record history shows the site revision updated to v3.6.6 (replacing v3.6.5). This reflects a software release rather than any modification to the trial data or records.
    Difference
    0.1%
    Check dated 2026-08-31T17:00:25.000Z thumbnail image
  6. Check
    65 days ago
    Change Detected
    Summary
    Introduction of a new 'Study Status' item in the history and a new version entry (version 21) dated 2026-07-24. An older entry dated 2026-05-12 was removed.
    Difference
    0.3%
    Check dated 2026-08-24T17:08:36.000Z thumbnail image

Stay in the know with updates to Trastuzumab Deruxtecan in HER2 Mutant NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Trastuzumab Deruxtecan in HER2 Mutant NSCLC Clinical Trial page.